DoMore Diagnostics
DoMore Diagnostics is a precision medicine company that leverages AI and digital pathology to personalize cancer treatment. Their core technology, Histotype Px®, utilizes AI algorithms to analyze routine tumor tissue slides and predict patient outcomes. This provides clinicians with objective and precise methods for cancer prognosis, aiming to reduce over- and undertreatment. The company was established based on research from leading institutions and has received EIC Accelerator funding. Their lead product, Histotype Px® Colorectal, is a CE-IVDD marked outcome prediction marker for colorectal cancer, guiding decisions on adjuvant chemotherapy. DoMore Diagnostics is committed to bringing AI-powered digital biomarkers closer to clinicians and patients to improve outcomes and lower healthcare costs.
DoMore Diagnostics
DoMore Diagnostics is a precision medicine company that leverages AI and digital pathology to personalize cancer treatment. Their core technology, Histotype Px®, utilizes AI algorithms to analyze routine tumor tissue slides and predict patient outcomes. This provides clinicians with objective and precise methods for cancer prognosis, aiming to reduce over- and undertreatment. The company was established based on research from leading institutions and has received EIC Accelerator funding. Their lead product, Histotype Px® Colorectal, is a CE-IVDD marked outcome prediction marker for colorectal cancer, guiding decisions on adjuvant chemotherapy. DoMore Diagnostics is committed to bringing AI-powered digital biomarkers closer to clinicians and patients to improve outcomes and lower healthcare costs.